Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet need. With each new discovery and experimental drug candidate, they seek to improve the care of patients suffering from life-threatening diseases.
Gileadâ€™s primary areas of focus include HIV/AIDS, liver disease and serious cardiovascular and respiratory conditions.
There portfolio of 13 marketed products includes a number of category firsts and market leaders, including AtriplaÂ® (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg) - the first single-tablet regimen for HIV infection. The companyâ€™s first product for HIV infection, VireadÂ® (tenofovir disoproxil fumarate), has also more recently been approved for the treatment of chronic hepatitis B. Chronic hepatitis B, a serious liver disease caused by the hepatitis B virus, is the leading cause of liver cancer worldwide and affects an estimated two million individuals in the United States.
Current Team (9)Update
Chairman and CEO, President and Chief Executive Officer
President and COO,Chief Financial Officer, Director of Project Management and Project Team Leader
Executive Vice President, Corporate and Medical Affairs, General Counsel, Associate General Counsel, Attorney
Senior Vice President and Chief Financial Officer
Senior Vice President, Human Resources
Senior Vice President Research
Executive Vice President, Research and Development and Chief Scientific Officer
Past Team (33)Update
Vice President, Commercial Strategy
Senior Vice President of Business Operations
1996 - Jan, 2000
Senior Vice President, Business Operations
MBA Intern - Finance
2006 - Jan, 2006
1997 - Oct, 2010
Senior Vice President, Manufacturing and Operations, Senior Member
333 Lakeside Drive
Foster City, CA 94404